Laekna Therapeutics closes $18.5mm Series A round
Executive Summary
Laekna Therapeutics Shanghai Co. Ltd. (developing both small-molecule and antibody-targeted drugs for cancer and liver diseases) raised $18.5mm through a Series A round led by OrbiMed Asia, with AnlongMed also participating. The 2016 start-up plans to use the funding to progress its pipeline. Laekna currently has three oncology candidates, including Phase II LAE001 (CFG920), an oral CYP17 inhibitor for prostate cancer, in-licensed from Novartis last year. It is also developing compounds for liver diseases, including NASH and hepatic cirrhosis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice